Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: Naso-oropharyngeal Antiseptic Decolonization for COVID-19
NCT04478019Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of povidone-iodine and chlorhexidine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Number of Participants with COVID-19 diagnosis at 8 weeks and SARS-Cov-2 Viral Load at 8 weeks. Started Jul 2020; status: completed.
02
Drugs
povidone-iodinechlorhexidine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04478019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478019.